Transcriptomics

Dataset Information

0

RNA-sequencing identifies global transcriptional changes in peripheral CD4+ cells during active esophagitis and following epicutaneous immunotherapy in eosinophilic esophagitis.


ABSTRACT: Immunotherapy strategies have been studied for IgE-mediated food allergies but have not been studied for non-IgE mediated food allergy disorders, including eosinophilic esophagitis. We interrogated the transcriptional signatures of peripheral CD4+ cells isolated from pediatric eosinophilic esophagitis patients enrolled in a phase IIa clinical trial of milk-antigen epicutaneous immunotherapy. We analyzed differential expression in peripheral CD4+ cells before therapy in patients before and after milk-exclusion diet. RNA-sequencing analysis revealed that there were 244 differentially expressed genes in peripheral blood CD4+ cells of EoE patients consuming milk versus those eliminating it, and 129 DEGs in CD4+ cells isolated after EPIT versus after placebo (FDR<0.05). Gene set enrichment analysis identifies enrichment of hallmark interferon-a and -g response signatures in peripheral CD4+ T cells from EoE patients during active disease on a milk-containing diet. In post-EPIT therapy samples, our analysis identifies enrichment in T-cell receptor signaling, antigen presentation, costimulation, and cytokine signaling pathways. These data suggest a unique peripheral CD4+ T cell gene signature is present in EoE patients during active disease. We observe a distinct transcriptional profile post-EPIT therapy in EoE patients, suggesting that EPIT alters CD4+ responses in EoE patients.

ORGANISM(S): Homo sapiens

PROVIDER: GSE173895 | GEO | 2021/08/03

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2014-09-01 | E-GEOD-55793 | biostudies-arrayexpress
2014-06-27 | E-GEOD-58640 | biostudies-arrayexpress
2021-08-13 | GSE175930 | GEO
2023-08-01 | PXD040030 | Pride
2020-08-22 | GSE156651 | GEO
2014-06-27 | GSE58640 | GEO
2023-08-10 | GSE228083 | GEO
2024-09-23 | PXD052250 | Pride
2019-02-08 | GSE126250 | GEO
2023-12-18 | GSE238122 | GEO